Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × gilteritinib × 1 year × Clear all

Phase

Phase 2 7 Phase 1/2 7 Phase 3 6 Phase 1 6 Phase NA 2 Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

Cisplatin 28 pembrolizumab 22 Magnetic Resonance Spectroscopy 22 Carboplatin 21 Paclitaxel 17 Gemcitabine 17 Specimen Handling 16 Oxaliplatin 15 Drug Therapy 15 atezolizumab 14 Nivolumab 14 Doxorubicin 14 Cyclophosphamide 14 Bevacizumab 14 Dexamethasone 13 Capecitabine 13 Radiotherapy 12 Pemetrexed 11 Docetaxel 11 Vincristine 10 Radiation 10 Prednisone 10 Cytarabine 10 venetoclax 9 Trastuzumab 9 Ipilimumab 9 Fluorouracil 9 Rituximab 8 Platinum 8 Etoposide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07425808 2026-02-23

FIT-AML

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡